Finerenon (3) – Kerendia®
Chronic heart failure with a left ventricular ejection fraction (LVEF) > 40%
Characteristics
| Start date | 01.05.2026 |
|---|---|
| Resolution | 15.10.2026 – active procedure |
| INN | Finerenon |
| Brand name | Kerendia® |
| Pharm. company | Bayer Vital GmbH |
| G-BA Procedure ID | D-1315 |
| Therapeutic area | Cardiovascular diseases |
| Reason for procedure | New therapeutic indication |
Associated procedures
| Finerenon (3) | Kerendia® | Bayer Vital GmbH | Chronic heart failure with a left ventricular ejection fraction (LVEF) > 40% | n.d. | active procedure | |
| Finerenon (2) | Kerendia® | Bayer Vital GmbH | Chronic kidney disease in type 2 diabetes, stages 1 and 2 with albuminuria | 436,400–493,750 | 100% Hint for non-quantifiable additional benefit | |
| Finerenon (1) | Kerendia® | Bayer Vital GmbH | Chronic kidney disease in type 2 diabetes, stages 3 and 4 with albuminuria | 304,500–322,500 | 100% additional benefit not proven |
<< List of all resolutions